Stay updated on Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.

Latest updates to the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a Phase III study involving durvalumab and the addition of new identifiers and collaborators related to endometrial neoplasms and drug treatments.SummaryDifference15%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 11, 2025. However, the deletion of the date March 25, 2025, indicates a potential change in scheduling or availability.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 11, 2025, and version 2.14.2.SummaryDifference0.2%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check80 days agoChange DetectedThe webpage has updated its date references, moving from November 2024 to February 2025, indicating a shift in the timeline of content. Additionally, there is a change in numerical values associated with the content, suggesting a possible update in data or statistics.SummaryDifference0.6%
Stay in the know with updates to Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.